T-ALL

CHOP researchers gain a new understanding of the genetic drivers of T-ALL, a particularly challenging childhood cancer.

In this Q&A, Drs. Teachey and Diorio discuss their partnership and research of a novel CAR T-cell therapy for one of the most common pediatric cancers.

Learn about novel findings and notable achievements from our Children’s Hospital of Philadelphia researchers.

Despite advances in T-cell acute lymphoblastic leukemia treatment, between 15 and 20 percent of children who achieve an initial complete remission will relapse. They may need more intensive therapy or alternative approaches, but physicians do not yet have a reliable way of predicting which patients are at high-risk of relapse.